Clinical Trial Update: Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine [Phase 3]

View source ↗

Summary

Phase 3 trial update on subcutaneous fremanezumab for preventive treatment of migraine; results completed with posted results in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• Fremanezumab (TEV-48125) (fremanezumab)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Migraine | Phase 3 | Status: COMPLETED | Results posted: 2019-08-28